Under-prescription of novel antiplatelet drugs in patients with acute coronary syndrome and previous cardiovascular disease
| Autor: | Orenes-Pinero E, Esteve-Pastor M, Ruiz-Nodar J, Quintana-Giner M, Veliz-Martinez A, Tello-Montoliu A, Macias-Villanego M, Pernias-Escrig V, Vicente-Ibarra N, Carrillo-Aleman L, Sandin-Rollan M, Martinez J, Lozano T, Rivera-Caravaca J, Marin F |
|---|---|
| Rok vydání: | 2019 |
| Předmět: | |
| Zdroj: | MINERVA MEDICA r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante Consejo Superior de Investigaciones Científicas (CSIC) |
| ISSN: | 0026-4806 |
| Popis: | BACKGROUND: Patients with acute coronary syndrome (ACS) and previous cardiovascular disease (CVD) (stroke, peripheral arterial disease [PAD] or coronary artery disease [CAD]) are at high risk of serious events and mortality. Current clinical guidelines recommend new antiplatelet drugs (NADs) for high cardiovascular risk patients with ACS; however, these drugs are underused in different scenarios. METHODS: This study included 1717 ACS patients from 3 tertiary hospitals. Of them, 641 (37.33%) suffered from previous CVD: 149 patients with stroke, 154 patients with PAD and 541 patients with CAD. Bleeding, mortality and major adverse cardiac events (MACE) at 1 year of follow-up after hospital discharge were analyzed. RESULTS: NADs administration during hospital stay and at discharge was less frequent in patients with previous CVDs (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|